[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-357029-105":59,"doc-detail-357029-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","malignant-ovarian-germ-cell-tumor-survival-and-reproductive-outcomes-and-patterns-of-relapse","Malignant Ovarian Germ Cell Tumor - Survival and Reproductive Outcomes and Patterns of Relapse","","Malignant ovarian germ cell tumors (MOGCTs) are rare cancers in young women, often diagnosed at advanced stages. A retrospective cohort evaluated survival outcomes for patients diagnosed between 2013 and 2018, using electronic medical records and Kaplan–Meier survival analysis. Among 170 patients, median age was 25 years, with stage distribution favoring early disease. Fertility-sparing surgery was commonly performed, with many resuming menstruation and reporting successful pregnancies, while certain relapses were not salvageable.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/malignant-ovarian-germ-cell-tumor-survival-and-reproductive-outcomes-and-patterns-of-relapse/357029/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/malignant-ovarian-germ-cell-tumor-survival-and-reproductive-outcomes-and-patterns-of-relapse/357029.png","ImageObject",300,407,{"name":92,"@type":93},"Mabel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What was the main objective of this study on MOGCT?","Question",{"text":113,"@type":114},"To evaluate survival outcomes and reproductive outcomes in patients treated for malignant ovarian germ cell tumors, with attention to disease characteristics and treatment results.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What study design and time period were used?",{"text":118,"@type":114},"A retrospective study of all MOGCT patients diagnosed from January 2013 to December 2018, with clinicopathologic and treatment data retrieved from electronic medical records.",{"name":120,"@type":111,"acceptedAnswer":121},"How did survival differ between early-stage and advanced-stage patients?",{"text":122,"@type":114},"The 5-year progression-free survival was higher for stage I/II than stage III/IV, while overall survival also remained higher for stage I/II compared with stage III/IV.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},357029,1790193885,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},7971474920318,"https://ap-avatar.wpscdn.com/avatar/74000ee537e6b0ca360?x-image-process=image/resize,m_fixed,w_180,h_180&k=1788430171632181674","Cancer Medicine  \nRESEARCH ARTICLE  OPEN ACCESS   \nMalignant Ovarian Germ Cell Tumor—Survival and Reproductive Outcomes and Patterns of Relapse  \nSayak Dey1 | Srikant Anne1 | Sushmita Rath1 | Ravindra Nandhana1 | Seema Gulia1  | Biswajit Dash2 | Santosh Menon3 | Bharat Rekhi3 | Akshay Baheti4 | Nilesh Sable4 | Palak Popat4 | Sandeep Tandon5 | Kinjalka Ghosh6 | Lavanya Gurram7 | Sarika Shivram Parab8 | Apenla N. Logkumer9 | Sunita Jhadhav8 | Supriya Chopra7 | Shylasree T. Surappa2 |  \nVandana Bansal10 | Geeta Balsarkar10 | Kedar Deodhar3 | Amita Maheshwari2  | Jaya Ghosh1  | Sudeep Gupta1   \n1Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India | 2Division of Gynecologic Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India | 3Department of Surgical Pathology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India | 4Department of Radiodiagnosis, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India | 5Department of Pulmonary Medicine, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India | 6Department of Biochemistry, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India | 7Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India | 8Medical Social Worker Department, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India | 9KEVAT, Patient Navigation Program, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India | 10Department of Obstetrics and Gynecology, Nowrosjee Wadia Maternity Hospital, Mumbai, India  \nCorrespondence: Jaya Ghosh ([archana_jaya_ghosh@yahoo.co.in](archana_jaya_ghosh@yahoo.co.in))  \nReceived: 25 May 2025 | Revised: 22 March 2026 | Accepted: 4 May 2026  \nKeywords: malignant ovarian germ cell tumor | neoadjuvant chemotherapy | patterns of relapse | reproductive outcome | survival  \nABSTRACT  \nBackground: Malignant ovarian germ cell tumors [MOGCT] are rare cancers affecting young women and often present in advanced stages. This study aimed to evaluate their survival outcomes.  \nMethods: This is a retrospective study of patients diagnosed with MOGCT between 2013 to 2018. Clinicopathologic data were retrieved from electronic medical records. Survival analysis was done using the Kaplan–Meier method.  \nResults: A total of 170 patients were analyzed. The median age was 25years (range: 15–68) . Histological subtypes were dysgerminoma 37%(n-63), yolk sac tumor 21%(n-36), Immature teratoma 21%(n-35), mixed germ cell tumor 17%(n-29), and mature teratoma with somatic malignancy 4%(n-7). Presentation in early stage (I and II) was 64%(n = 108), while 36%(n = 62) had advanced stage (Stage III/IV) . Chemotherapy was received by 134 patients, of whom 49 received it in a neoadjuvant setting. Most patients (n = 134–79%) underwent fertility-sparing surgery, of whom 87%(117 of 134) resumed menstruation after completion of chemotherapy, with 18 successful pregnancies. Patients with relapsed yolk sac tumors (4) presented with ascites and peritoneal disease and could not be salvaged. Median follow-up was 62 months [range 58–65months]. The 5-year progression-free survival for stage I/II was 86%(95% CI 79–93) and for stage III/IV was 70%(95% CI 58–82). The 5-year overall survival for stage I/II was 99%[95% CI 97–100] and for Stage III/IV was 88%(95% CI 79–97) .  \nConclusions: Patients presenting with advanced MOGCT can be offered fertility-sparing surgery after neoadjuvant chemotherapy with no detriment in oncological outcome.  \nThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.  \n© 2026 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.  \nCancer Medicine, 2026; 15:e71936 1 of 10  \n[https://doi.org/","cbCailcPJc1dEPeq","https://ap.wps.com/l/cbCailcPJc1dEPeq","pdf",641411,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n# Materials and Methods\n## Study Design and Participants","[{\"question\":\"What was the main objective of this study on MOGCT?\",\"answer\":\"To evaluate survival outcomes and reproductive outcomes in patients treated for malignant ovarian germ cell tumors, with attention to disease characteristics and treatment results.\"},{\"question\":\"What study design and time period were used?\",\"answer\":\"A retrospective study of all MOGCT patients diagnosed from January 2013 to December 2018, with clinicopathologic and treatment data retrieved from electronic medical records.\"},{\"question\":\"How did survival differ between early-stage and advanced-stage patients?\",\"answer\":\"The 5-year progression-free survival was higher for stage I/II than stage III/IV, while overall survival also remained higher for stage I/II compared with stage III/IV.\"}]","Malignant Ovarian Germ Cell Tumor - Survival and Reproductive Outcomes and Patterns of Relapse | PDF",1790128651,25,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/83308e5b95be148095e043dd9d12f3d3.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7019b881cb8fe28bea4c52fbc93061c.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0cfe24d1612efd24a244a3ab8df0b02f.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8e5abbd607d4bd872d40da0c823f0b3b.webp",980,1287]